(lp0
S'Idera Pharma Shares Could Be A Four-Bagger, JMP Says Benzinga - 18 hours ago Idera Pharmaceuticals Inc  is a clinical-stage biopharmaceutical company developing novel nucleic acid-based product candidates for the treatment of cancer and rare diseases.Idera Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 22 - Equities.comAnalyst Activity  JMP Securities Initiates Coverage On Idera Pharmaceuticals ... - Market Exclusive'
p1
aS"Revenue Approximations Analysis: Washington Prime Group Inc. , Idera ... StockNewsJournal - 15 hours ago The average of this ratio is -2.57 for the industry and sector's best figure appears 13.02. Idera Pharmaceuticals, Inc. , at its latest closing price of $2.09, it has a price-to-book ratio of 3.22, compared to an industry average at 10.15 ..."
p2
aS"Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially ... Seeking Alpha - Feb 27, 2017 Idera Pharmaceuticals  is a clinical-stage biopharmaceutical company developing novel nucleic acid based therapies for the treatment of certain cancers and rare diseases.Stock Movers  MannKind Corporation , Idera Pharmaceuticals Inc ... - Wall Street Times Volatility Analysis: Idera Pharmaceuticals, Inc.  - The Oracle Examiner"
p3
aS'Idera Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 21 Equities.com - Mar 21, 2017 Idera Pharmaceuticals Inc.  traded on unusually high volume on Mar. 21, as the stock lost 6.28% to close at $2.09. On the day, Idera Pharmaceuticals Inc. saw 2.75 million shares trade hands on 7,181 trades. Considering that the stock averages ...'
p4
aS'Idera Pharmaceuticals Inc.  Soars 8.25% on March 20 Equities.com - Mar 20, 2017 Idera Pharmaceuticals Inc.  had a good day on the market for Monday March 20 as shares jumped 8.25% to close at $2.23.Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial ... - GlobeNewswire Stock Volatility Risk Alert: Idera Pharmaceuticals Inc Price Volatility Hits ... - CML News'
p5
aS'Idera Pharmaceuticals Inc  Reports Additional Phase 1/2 Data In ... Smarter Analyst - Feb 24, 2017 Idera Pharmaceuticals Inc  is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with ipilimumab or pembrolizumab for treatment of&nbsp;...Analyst Activity  Wedbush Reiterates Outperform on Idera Pharmaceuticals ... - Market Exclusive'
p6
aS'Brokerage Firm Analyst Consensus on Duluth Holdings Inc.  Idera ... Rives Journal - 17 hours ago Stock research firms currently have a positive stance on shares of Duluth Holdings Inc. . Analysts are projecting that the stock will reach $29.40 on a short term  basis.'
p7
aS'Idera Pharmaceuticals  Looks Good: Stock Up 13.3% March 01, 2017 Zacks.com - Mar 1, 2017 Idera Pharmaceuticals, Inc.  was a big mover last session, as the company saw its shares rise over 13% on the day.'
p8
aS"A Keen Look At The Chart For Idera Pharmaceuticals, Inc.  NY Stock News - 16 hours ago Idera Pharmaceuticals, Inc.  has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment."
p9
aS"JMP Securities Analyzed Idera Pharma ; Berkshire Hathaway Lifted Delta ... Herald KS - 17 hours ago Analysts await Idera Pharmaceuticals Inc  to report earnings on May, 8. They expect $-0.10 earnings per share, up 9.09% or $0.01 from last year's $-0.11 per share."
p10
a.